{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T01:17:59Z","timestamp":1771982279017,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cytopathology"],"published-print":{"date-parts":[[2018,12]]},"abstract":"Background<\/jats:title>A feared complication of thyroid fine needle aspiration (FNA<\/jats:styled-content>) is bleeding diathesis and haematoma at the biopsy site. Patients are often advised to discontinue antithrombotic\/anticoagulant (AT<\/jats:styled-content>\/AC<\/jats:styled-content>) medications prior to the procedure. The aim of this study was to examine the risk of bleeding in patients on AT<\/jats:styled-content>\/AC<\/jats:styled-content> medications undergoing cervical ultrasound (US<\/jats:styled-content>)\u2010guided FNA<\/jats:styled-content>.<\/jats:p><\/jats:sec>Methods<\/jats:title>A retrospective chart review of 803 patients who underwent US<\/jats:styled-content>\u2010guided FNA<\/jats:styled-content> of thyroid nodules over 8\u00a0years by a single endocrine surgeon was undertaken. Clinical variables, patient demographics and use of AT<\/jats:styled-content>\/AC<\/jats:styled-content> medications were collected and analysed. The principle outcome measures included the incidence of procedure\u2010related haematoma formation. Multivariable logistic regression was used to investigate the possible independent association between post\u2010FNA<\/jats:styled-content> haematoma and anticoagulation, adjusting for age, African American race, body mass index, vascularity and lesion size.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 1568 lesions were included in 803 patients. The mean age for the patients on AT<\/jats:styled-content>\/AC<\/jats:styled-content> was 63.0\u00a0\u00b1\u00a010.4\u00a0years and those not on AT<\/jats:styled-content>\/AC<\/jats:styled-content> was 50.1\u00a0\u00b1\u00a014.2\u00a0years (P<\/jats:italic>\u00a0<\u00a00.001). Of those, 148 patients had 336 lesions (21%) biopsied while taking one or more daily AT<\/jats:styled-content>\/AC<\/jats:styled-content> agent (81 patients: aspirin; 11 patients: Plavix; 17 patients: aspirin and warfarin; 30 patients: aspirin and Plavix; seven patients: rivaroxaban and aspirin; and two patients: ticagrelor and aspirin). Three patients (0.89%) in the AT<\/jats:styled-content>\/AC<\/jats:styled-content> group compared to six patients (0.49%) not receiving AT<\/jats:styled-content>\/AC<\/jats:styled-content> medications developed a haematoma (P<\/jats:italic>\u00a0=\u00a00.41). All complications were treated conservatively and none required intervention.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>US<\/jats:styled-content>\u2010guided FNA<\/jats:styled-content> of thyroid lesions can be safely performed on patients taking AT<\/jats:styled-content>\/AC<\/jats:styled-content> including newer agents, without an increase in adverse outcomes or decreased diagnostic rate. Further larger prospective multi\u2010institutional studies are warranted to further investigate this important finding.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cyt.12608","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T14:56:29Z","timestamp":1530629789000},"page":"565-568","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Do anticoagulation medications increase the risk of haematoma in ultrasound\u2010guided fine needle aspiration of thyroid lesions?"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9247-7145","authenticated-orcid":false,"given":"Helmi","family":"Khadra","sequence":"first","affiliation":[{"name":"Division of Endocrine and Oncologic Surgery Department of Surgery Tulane University School of Medicine New Orleans Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roostam","family":"Kholmatov","sequence":"additional","affiliation":[{"name":"Division of Endocrine and Oncologic Surgery Department of Surgery Tulane University School of Medicine New Orleans Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Monlezun","sequence":"additional","affiliation":[{"name":"Division of Endocrine and Oncologic Surgery Department of Surgery Tulane University School of Medicine New Orleans Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emad","family":"Kandil","sequence":"additional","affiliation":[{"name":"Division of Endocrine and Oncologic Surgery Department of Surgery Tulane University School of Medicine New Orleans Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.0110"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1058082"},{"key":"e_1_2_6_4_1","first-page":"845\u2010858","article-title":"Cardiovascular risk associated with interruption of antiplatelet and oral anticoagulation therapy","volume":"28","author":"Ferreira JS","year":"2009","journal-title":"Rev Port Cardiol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03522.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.12.9930"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.07.3537"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.4111\/kju.2012.53.4.234"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/RUQ.0b013e31822b5681"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0307"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.7863\/jum.2011.30.5.685"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.14.13342"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2012.02.012"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2015.16.2.391"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02499.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.23"}],"container-title":["Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcyt.12608","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cyt.12608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T20:16:06Z","timestamp":1694808966000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cyt.12608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,3]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/cyt.12608"],"URL":"https:\/\/doi.org\/10.1111\/cyt.12608","archive":["Portico"],"relation":{},"ISSN":["0956-5507","1365-2303"],"issn-type":[{"value":"0956-5507","type":"print"},{"value":"1365-2303","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,3]]},"assertion":[{"value":"2018-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}